Localized Scleroderma clinical trials

Explore recruiting localized scleroderma clinical trials.

Recruiting localized scleroderma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Localized Scleroderma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized scleroderma (LEMO)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Localized Scleroderma trials by city

Localized Scleroderma in Toronto Localized Scleroderma in Vancouver Localized Scleroderma in Montreal Localized Scleroderma in Calgary Localized Scleroderma in Edmonton Localized Scleroderma in Ottawa Localized Scleroderma in Winnipeg Localized Scleroderma in Quebec City Localized Scleroderma in Hamilton Localized Scleroderma in Kitchener Localized Scleroderma in London Localized Scleroderma in Halifax Localized Scleroderma in New York Localized Scleroderma in Los Angeles Localized Scleroderma in Chicago Localized Scleroderma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease